Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.58 and traded as high as $0.63. Protagenic Therapeutics shares last traded at $0.55, with a volume of 110,680 shares.
Protagenic Therapeutics Stock Down 4.0 %
The business's 50 day simple moving average is $0.47 and its 200-day simple moving average is $0.58. The company has a market cap of $9.49 million, a price-to-earnings ratio of -2.51 and a beta of 0.06. The company has a debt-to-equity ratio of 0.04, a quick ratio of 14.93 and a current ratio of 14.93.
Get
Protagenic Therapeutics alerts:
Protagenic Therapeutics (OTCMKTS:PTIX – Get Rating) last issued its earnings results on Monday, November 14th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter.
Institutional Investors Weigh In On Protagenic Therapeutics
An institutional investor recently raised its position in Protagenic Therapeutics stock. Renaissance Technologies LLC boosted its position in shares of Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) by 69.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 102,200 shares of the biotechnology company's stock after acquiring an additional 41,800 shares during the period. Renaissance Technologies LLC owned 0.59% of Protagenic Therapeutics worth $83,000 at the end of the most recent quarter. Institutional investors own 3.47% of the company's stock.
Protagenic Therapeutics Company Profile
(Get Rating)
Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
Further Reading
- Get a free copy of the StockNews.com research report on Protagenic Therapeutics (PTIX)
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.58 and traded as high as $0.63. Protagenic Therapeutics shares last traded at $0.55, with a volume of 110,680 shares.
Protagenic Therapeutics, Inc.（OTCMKTS: PTIX — 获取评级）在周四的交易中突破了其200日移动平均线。该股的200天移动平均线为0.58美元，交易价格高达0.63美元。Protagenic Therapeutics股票最后一次交易价格为0.55美元，成交量为110,680股。
Protagenic Therapeutics Stock Down 4.0 %
Protagenic Therapeutics 股票下跌
The business's 50 day simple moving average is $0.47 and its 200-day simple moving average is $0.58. The company has a market cap of $9.49 million, a price-to-earnings ratio of -2.51 and a beta of 0.06. The company has a debt-to-equity ratio of 0.04, a quick ratio of 14.93 and a current ratio of 14.93.
该公司的50天简单移动平均线为0.47美元，其200天简单移动平均线为0.58美元。该公司的市值为949万美元，市盈率为-2.51，beta为0.06。该公司的债务与权益比率为0.04，速动比率为14.93，流动比率为14.93。
Get
Protagenic Therapeutics
alerts:
Protagenic Therapeutics (OTCMKTS:PTIX – Get Rating) last issued its earnings results on Monday, November 14th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter.
Protagenic Therapeutics（OTCMKTS: PTIX — 获取评级）最后一次发布财报是在11月14日星期一。这家生物技术公司报告了本季度每股收益（EPS）（0.05美元）。
Institutional Investors Weigh In On Protagenic Therapeutics
机构投资者对 Protagenic Therapeutics 表示关注
An institutional investor recently raised its position in Protagenic Therapeutics stock. Renaissance Technologies LLC boosted its position in shares of Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) by 69.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 102,200 shares of the biotechnology company's stock after acquiring an additional 41,800 shares during the period. Renaissance Technologies LLC owned 0.59% of Protagenic Therapeutics worth $83,000 at the end of the most recent quarter. Institutional investors own 3.47% of the company's stock.
一位机构投资者最近提高了其在Protagenic Therapeutics股票中的头寸。Renaissance Technologies LLC在向美国证券交易委员会（SEC）提交的最新13F文件中显示，该公司在第一季度将其在Protagenic Therapeutics, Inc.（OTCMKTS: PTIX — 获取评级）的股票头寸提高了69.2％。该基金在此期间又收购了41,800股股票后，拥有该生物技术公司的102,200股股票。截至最近一个季度末，文艺复兴科技有限责任公司拥有Protagenic Therapeutics0.59％的股份，价值83,000美元。机构投资者拥有该公司3.47％的股票。
Protagenic Therapeutics Company Profile
Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
Protagenic Therapeutics, Inc是一家生物制药公司，从事治疗与压力相关的神经精神疾病和情绪障碍的疗法的发现和开发。其主要化合物是 PT00114，这是一种合成形式的 teneurin carboxy-末端相关肽，一种可以抑制过度活跃的应激反应的内源性大脑信号肽。
Further Reading
- Get a free copy of the StockNews.com research report on Protagenic Therapeutics (PTIX)
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
- 免费获取 StockNews.com 关于 Protagenic Therapeutics (PTIX) 的研究报告
- 埃克森美孚股票：距离买入点仅几步之遥
- 高股息收益的必和必拓认为中国将推动 “23” 的增长
- Airbnb是否准备像分析师所预测的那样上涨38％？
- 特斯拉汽车降价对TSLA股票意味着同样的吗？
- 微软裁员预示着其他科技公司的裁员？
Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收 Protagenic Therapeutics 的新闻和评 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Protagenic Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。
